Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

New leukemia drug suppresses cancer-driving protein more strongly than existing treatments within one week (opens in a new tab)

medicalxpress.com · 2026-10-27

Short answerEvidenceSource

Short answer

Not assessed

Check incomplete.

We found a likely source study, but its evidence could not be prepared for claim review. The article's claims remain unverified.

Share this check

Follow the evidence trail
1

The story

New leukemia drug suppresses cancer-driving protein more strongly than existing treatments within one week

medicalxpress.com · 2026-10-27

The story’s checkable claims.

Read the original story (opens in a new tab)
2

NewsLink checks it

Source study identified.

A source study was identified, but the study's evidence could not be prepared for claim assessment. No claim verdicts are available.

View article claims
3
Source paper

Source layer

The 2 papers the story cites

Source study separated from background citations.

The research anchor for the report.

Then inspect each claim

Evidence layer

Claim by claim

A source study was identified, but the study's evidence could not be prepared for claim assessment. The claims below have not been assessed.

Claim 1 of 5Not checkedWithin just one week, asciminib achieved substantially stronger suppression of the cancer-driving protein than the currently available treatments, and none of the patients experienced the poorer responses sometimes seen with the existing drugs.View evidenceHide evidence

As statedwithin just one week; substantially stronger

Not checked

A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.

Claim 2 of 5Not checkedA new study led by Adelaide University and SAHMRI provided the first direct evidence that a targeted therapy can rapidly and consistently suppress the molecular signals that drive chronic myeloid leukemia.View evidenceHide evidence

As statedrapidly and consistently

Not checked

A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.

Claim 3 of 5Not checkedThe researchers compared asciminib with the tyrosine kinase inhibitors imatinib and nilotinib and found asciminib was much more powerful at suppressing the cancer-driving protein.View evidenceHide evidence

As statedmuch more powerful

Not checked

A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.

Claim 4 of 5Not checkedResearchers also investigated asciminib in patients with a specific genetic mutation linked to treatment failure and found it could still block the main driver of abnormal cell growth, though other factors may still affect outcomes.View evidenceHide evidence

Not checked

A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.

Claim 5 of 5Not checkedThe findings were published in Leukemia and are presented as evidence that could help doctors identify earlier whether a patient is responding well to treatment and tailor therapy sooner.View evidenceHide evidence

As statedcould help

Not checked

A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Crossref, Europe PMC · 33 candidate papers

Candidate

Myelodysplastic Neoplasm and Acute Myeloid Leukemia: Multi-Omics Approaches and Precision Medicine

Frontiers Research Topics · 2026 · Crossref

Source (opens in a new tab)

And 27 more candidates considered.